Search

A recent study conducted at Morgan State University explored the interaction of 6-thioguanine (6-TG) with an aluminum metal-organic framework (Al-MOF) to achieve delayed drug release for the treatment of leukemia. The research utilized mechano-chemistry to study the bonding of 6-TG to the matrix, resulting in a significantly slower release of the drug compared to pure 6-TG. The composite showed a time-dependent stronger inhibition of leukemia cell colonies, indicating potential therapeutic benefits. This study sheds light on innovative approaches to drug delivery and treatment strategies for leukemia. [Extracted from the article]

Researchers at Xinxiang Medical University in China have developed a nanocarrier called FPSD NPs that targets breast cancer cells by delivering doxorubicin in combination with decitabine. This treatment approach significantly increased the expression of the GSDME protein in cancer cells, leading to pyroptosis, a form of programmed cell death. In vivo experiments showed that the treatment reduced tumor volumes, increased T cell presence, and promoted antitumor immunity, offering a promising avenue for breast cancer therapy. The study was peer-reviewed and published in ACS Applied Materials & Interfaces. [Extracted from the article]

Researchers at the Department of Pharmacy Practice have formulated and characterized biodegradable nanospheres containing 5-fluorouracil and metformin for treating colon cancer. The nanoparticles were found to have excellent physiochemical properties, controlled drug release, and demonstrated effectiveness in inhibiting cell proliferation in colorectal carcinoma cells. The study highlights the potential of this novel formulation in improving cancer treatment outcomes, particularly in patients with type 2 diabetes mellitus. [Extracted from the article]

The article discusses a clinical trial, NCT06660368, focusing on combining CLAG-based therapy with or without venetoclax in patients with relapsed or refractory acute myeloid leukemia (AML) to improve measurable residual disease clearance and event-free survival. The study aims to determine if adding venetoclax to CLAG-M is safe and superior to CLAG-M alone in enhancing patient outcomes. The trial is not yet recruiting participants, with a primary completion date set for November 30, 2027, and is being conducted by the H. Lee Moffitt Cancer Center and Research Institute in the United States. [Extracted from the article]

Researchers at Shanghai Jiao Tong University have identified GALNT5 as a key factor in conferring resistance to FOLFIRINOX chemotherapy in pancreatic ductal adenocarcinoma (PDAC). Through various assays and analyses, they found that GALNT5 inhibits DNA damage and activates the NOTCH pathway, leading to chemotherapy resistance and poor prognosis in PDAC patients. This study suggests that GALNT5 could be a potential therapeutic target for PDAC patients resistant to FOLFIRINOX chemotherapy. [Extracted from the article]

A recent study conducted at the Affiliated Hospital of North Sichuan Medical College compared the effectiveness and safety of 5-Fluorouracil (5-Fu) combined with conventional transarterial chemoembolization (cTACE) versus 5-Fu combined with drug-eluting bead transarterial chemoembolization (DEB-TACE) using CalliSpheres for treating unresectable hepatocellular carcinoma (HCC). The study found that 5-Fu-DEB-TACE showed superior therapeutic efficacy, prolonged progression-free survival (PFS), and reduced hepatotoxicity compared to 5-Fu-cTACE, although it was associated with a higher incidence of postoperative abdominal pain. The research concluded that 5-Fu-DEB-TACE may be a more effective treatment option for HCC patients. [Extracted from the article]

A recent study from Universidad del Bio-Bio in Concepcion, Chile, focused on the development of macrocapsules containing gemcitabine for targeted cancer therapy and antibacterial defense. The study successfully produced capsules with high gemcitabine encapsulation efficiency and controlled release, showing potential for reduced dosing requirements and fewer side effects. These macrocapsules also demonstrated potent antimicrobial activity, making them a promising dual-action agent for treating lung cancer in patients at risk of infectious diseases or who are immunosuppressed. [Extracted from the article]

A study conducted by the National Autonomous University of Mexico (UNAM) in Leon focused on the development of a novel drug-loaded nanocarrier using titanium dioxide nanoparticles surface functionalized with 5-fluorouracil (5-FU) to enhance drug delivery for oral cancer treatment. The research aimed to address drug resistance issues commonly encountered during 5-FU chemotherapy. Results showed that the drug-loaded nanocarrier exhibited increased antitumor effects in oral cancer cell lines while minimizing cytotoxicity to human gingival fibroblasts. This study highlights the potential effectiveness of the TiO2/5-FU system in the tumor microenvironment. [Extracted from the article]

A patent application titled "APTAMER-siRNA FUSIONS" was published online by inventors HABIB, Nagy and VASCONCELOS, Luis. The application focuses on developing ribonucleic acid compounds for targeted delivery of therapeutic payloads to cancer cells, specifically pancreatic ductal adenocarcinoma (PDAC) with liver metastasis. The compounds consist of aptamers capable of binding to transferrin receptors and CCAAT/enhancer-binding protein b (C/EBPb) siRNA, offering potential advancements in cancer treatment. The patent application highlights the need for improved targeted therapeutic delivery methods in cancer treatment. [Extracted from the article]

A patent application by inventor Thomas H. Adams proposes a combination therapy for the treatment of Pan-Kras mutated cancers, focusing on the use of the CDK inhibitor milciclib in conjunction with other anticancer drugs. The application highlights the potential efficacy of milciclib in inhibiting cancer cell proliferation and suggests that combining it with a tyrosine kinase inhibitor could enhance anti-tumorigenic activity. The therapy targets KRAS mutations, particularly the prevalent KRAS G12C mutation in non-small cell lung cancer, aiming to address the unmet need for effective treatments in this patient population. [Extracted from the article]

A retrospective cohort study conducted at Tsinghua University in Beijing, China, compared the efficacy of a novel treatment regimen for advanced biliary tract cancer (BTC) with standard chemotherapy options. The study found that the novel regimen, which included hepatic artery infusion chemotherapy with mFOLFOX-HAIC, lenvatinib, and PD-1 inhibitors, demonstrated superior progression-free survival and overall survival compared to standard regimens. The research concluded that the new treatment appears to be safe and well-tolerated for advanced BTC patients. [Extracted from the article]

A study conducted at Tanta University in Egypt compared the efficacy of two chemotherapy regimens, docetaxel, cisplatin, and 5-fluorouracil (TPF) and gemcitabine/cisplatin (GP), in treating patients with locally advanced nasopharyngeal carcinoma (NPC). The research found that both regimens had a high overall response rate after induction chemotherapy, with the GP regimen showing lower rates of severe side effects compared to the TPF regimen. The study concluded that there was no significant difference in the 3-year disease-free survival and overall survival between the two protocols. [Extracted from the article]

A recent study conducted by researchers at the University of Iowa focused on the use of pharmacological ascorbate (P-AscH-) in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic cancer. The study found that adding P-AscH- to the treatment regimen increased overall survival to 16 months compared to 8.3 months without it. Importantly, the addition of P-AscH- did not negatively impact quality of life or increase adverse events for patients. This research offers promising results for improving outcomes in patients with metastatic pancreatic cancer. [Extracted from the article]

A randomized phase 2 trial is being conducted to compare the effectiveness of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). ASTX727 is a combination of two drugs, cedazuridine and decitabine, which work to produce normal blood cells and kill abnormal cells in the bone marrow. Iadademstat may stop tumor cell growth by blocking enzymes needed for cell growth. The trial aims to assess acute leukemia response rates, event-free survival, overall survival, and other outcomes in patients with MPNs. [Extracted from the article]

The article discusses an exploratory clinical trial, NCT06658951, evaluating the safety and preliminary efficacy of Anti-HER2 CAR-T cell injection in patients with HER2-positive advanced malignant solid tumors. The trial aims to determine the maximum tolerated dose of the injection and assess its safety and efficacy. The study is currently not recruiting participants, with a planned completion date of November 30, 2026, and is being conducted in China. The trial includes specific eligibility criteria and outcome measures to evaluate the effectiveness of the treatment. [Extracted from the article]

A clinical trial, NCT06662877, is being conducted to evaluate the efficacy of Anlotinib plus Nab-Paclitaxels and S-1 as a second-line treatment for advanced biliary tract cancer (BTC) compared to the standard FOLFOX regimen. The trial aims to improve treatment outcomes for patients with BTC, which has a low 5-year survival rate. The study will assess overall survival, progression-free survival, objective response rate, disease control rate, quality of life, and adverse events as primary and secondary outcome measures. The trial is set to start on November 25, 2024, with a primary completion date of September 1, 2029. [Extracted from the article]

A research study conducted at Aristotle University of Thessaloniki in Greece focused on the association between SLC19A1 gene polymorphisms and regulatory miRNAs with methotrexate toxicity in children with Acute Lymphoblastic Leukemia (ALL). The study found a statistically significant correlation between the rs1131596 polymorphism and the development of methotrexate-induced hepatotoxicity in patients with ALL. Additionally, the presence of genotype TT of rs1131596 and genotype AA of rs56292801 in a patient increased the risk of severe hepatotoxicity. The study did not find significant associations between the studied polymorphisms and other side effects such as mucositis, nausea, emesis, diarrhea, neutropenia, skin rash, and infections. [Extracted from the article]

The article discusses a phase 1 clinical trial, NCT06654037, testing the safety and efficacy of abemaciclib in combination with 5-fluorouracil for treating metastatic, refractory colorectal cancer. Abemaciclib, a cyclin-dependent kinase inhibitor, and 5-fluorouracil, an antimetabolite, are being studied for their potential to inhibit tumor growth and kill cancer cells. The trial aims to determine the maximum tolerated dose, anti-tumor activity, pharmacodynamics, and pharmacokinetics of the combination therapy. The study is currently in the recruitment phase and aims to enroll 39 participants by December 1, 2026. [Extracted from the article]

The article discusses a study that explores the mechanisms of action of the drug decitabine in treating high-risk acute myeloid leukemia (AML). Using a multiomics approach, researchers found that RNA dynamics play a crucial role in promoting cellular sensitivity to DNA hypomethylation induced cell death by decitabine. The study highlights the importance of understanding cancer vulnerabilities and drug mechanisms to develop effective cancer therapies. The preprint has not yet undergone peer review. [Extracted from the article]

A recent report from the University of Campania highlights the potential of combining curcumin and methotrexate for the treatment of osteosarcomas. The study suggests that curcumin, known for its antioxidant and anti-cancer properties, can downregulate components of the Hedgehog signaling pathway involved in tumorigenesis, inhibiting cancer progression. By targeting this pathway, curcumin and methotrexate showed promising pro-apoptotic effects, reducing the adverse effects of current therapies. This research offers new insights into potential therapeutic strategies for osteosarcoma treatment. [Extracted from the article]

A recent study conducted at the Kalasalingam Academy of Research and Education in Krishnankoil, India, explored the combinatory effect of Gemcitabine and 5-fluorouracil (GE5F) in targeting breast cancer cells. The research highlighted that co-delivering these FDA-approved drugs can enhance biological activity by targeting different protein mechanisms simultaneously, potentially increasing efficacy in fighting breast cancer. The study utilized molecular dynamics simulations and chemoinformatics to investigate the structural stability, reactivity, and interactions of the GE5F adduct, showing promising results for future in vitro and in vivo experiments. [Extracted from the article]

A clinical trial, NCT06652412, is being conducted to study the effects of Ultrafractionated Radiotherapy and Comprehensive Geriatric Assessment (CGA) Guided systemic treatment on elderly or frail patients with inoperable localized colorectal cancer. Patients will be classified as Frail, Vulnerable, or Fit based on CGA results, with corresponding treatment plans. The primary endpoint is the complete response rate, with secondary endpoints including adverse effects, anal preservation rate, and survival. The trial aims to provide valuable insights into the treatment of colorectal cancer in older or frail patients. [Extracted from the article]

Researchers from the University of Florida Research Foundation Inc. have submitted a patent application for a method that involves characterizing subjects with cancer, particularly leukemia, based on their genotype scores. The method aims to personalize treatment plans by administering cytarabine at tailored dosages according to the subject's genetic makeup. This approach could potentially improve outcomes for individuals with leukemia, including pediatric patients, by optimizing therapy augmentation. The patent application outlines specific SNP locations and genotype scoring methods to guide personalized therapy decisions in acute myeloid leukemia (AML) cases. [Extracted from the article]

A clinical trial, NCT06652139, is being conducted at Ruijin Hospital to evaluate the efficacy and safety of selinexor combined with BEAM as a preconditioning regimen for autologous stem cell transplantation in patients with relapsed and refractory diffuse large B-cell lymphoma with MYC positivity. The trial involves 82 patients who will be randomly assigned to receive either the experimental selinexor combined with BEAM regimen or the control BEAM regimen before undergoing ASCT therapy. The primary outcome measures include progression-free survival, overall survival, complete remission rate, time of hematopoietic reconstruction, and transplantation-related adverse reactions. [Extracted from the article]

The article discusses a Phase Ib/II clinical study (NCT06646055) evaluating the safety and efficacy of AK112 and Cadonilimab combined with chemotherapy as a first-line treatment for metastatic pancreatic cancer. The trial includes stage IV pancreatic cancer patients with an ECOG performance status of 0-1. The study aims to assess the frequency of adverse events, overall response rate, pharmacokinetics, anti-drug antibodies, progression-free survival, overall survival, disease control rate, duration of response, and time to response. [Extracted from the article]

Researchers from Mazandaran University of Medical Sciences conducted a study on the impact of glutamine mouthwash in preventing mucositis in children with acute lymphoblastic leukemia undergoing high-dose methotrexate therapy. The randomized clinical trial included 45 patients, with the intervention group receiving glutamine mouthwash and the control group receiving a placebo. The study found that glutamine mouthwash significantly reduced the incidence of nausea and vomiting, and up to 95% of patients were free from mucositis by the seventh day post-chemotherapy. The research was published in the Middle East Journal of Cancer. [Extracted from the article]

The article explores the impact of capecitabine therapy on the gut microbiota of colorectal cancer patients through metagenomic analysis. The study found that capecitabine treatment altered microbial composition, leading to an increase in menaquinol biosynthesis genes which protected bacteria from drug toxicity. Machine learning models were used to predict drug toxicities based on microbiome profiling. The findings suggest that microbial vitamin biosynthesis may play a chemoprotective role, with implications for reducing drug toxicities in cancer patients. [Extracted from the article]

The article discusses a clinical trial, NCT06643962, focusing on the efficacy and safety of combining Venetoclax with intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia and lower early peripheral blast clearance rates after standard induction therapy. The trial aims to evaluate outcomes such as complete remission rates, event-free survival, relapse-free survival, and overall survival. Eligibility criteria include age between 18-70, fitness for intensive chemotherapy, and specific health parameters. The study is not yet recruiting, with an enrollment target of 83 participants and a completion date of October 31, 2027. [Extracted from the article]

A study conducted in Cairo, Egypt, examined the efficacy of endobronchial intratumoral injection of 5-Fluorouracil as a chemotherapeutic agent in palliative care for patients with inoperable nonsmall-cell lung cancer (NSCLC). The research concluded that this treatment approach was not effective in improving outcomes for patients with advanced malignant endobronchial NSCLC. The study involved 30 patients and found no significant difference in tumor response between those who received systemic chemotherapy alone and those who received systemic chemotherapy along with local chemotherapy using 5-fluorouracil. The findings were published in The Egyptian Journal of Chest Diseases and Tuberculosis. [Extracted from the article]

The article discusses a study that utilized Molecular Pixelation (MPX) to analyze changes in the cell surface proteome of leukemia cells treated with fludarabine, a chemotherapeutic agent. The research focused on the ETV6::RUNX1 acute lymphoblastic leukemia (ALL) cell line, Reh, and identified alterations in protein abundance, polarity, and colocalization post-treatment. The study highlighted the potential therapeutic implications of certain proteins, such as CD82 and CD53, in chemotherapy resistance. This research showcases the value of spatially resolved single-cell proteomics in uncovering subtle cellular responses. [Extracted from the article]

A study conducted at Sun Yat-sen University in Guangzhou, China, explored the effectiveness of capecitabine plus PD-1 antibody as maintenance therapy in advanced or metastatic gastric cancer patients who had received oxaliplatin-based chemotherapy. The research found that patients maintained with capecitabine plus PD-1 antibody had significantly longer progression-free survival and overall survival compared to those on capecitabine monotherapy. Subgroup analysis indicated that patients with high expression of PD-L1 or low levels of CXCL12 benefited more from the maintenance therapy. This study provides valuable insights into potential treatment options for gastric cancer patients. [Extracted from the article]

A clinical trial, NCT06640582, is investigating the safety and efficacy of combining autologous tumor-infiltrating lymphocytes (TIL) therapy with Pembrolizumab immunotherapy for patients with advanced brain cancer, including gliomas and meningiomas. This personalized treatment approach aims to utilize the patient's own immune cells to combat cancer, similar to the success seen in treating melanoma. The trial's primary endpoint is to determine the objective response rate (ORR), with secondary endpoints including disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and quality of life (QoL). This study offers a novel treatment option for patients with limited therapeutic alternatives. [Extracted from the article]

A patent issued by Johns Hopkins University discusses a method to increase the therapeutic efficiency of oncolytic bacterial therapy for solid tumors. The patent focuses on using immunoregulatory compounds, such as hydroxyurea, to suppress neutrophils before administering anaerobic bacteria to treat tumors. This approach aims to enhance tumor clearance and reduce treatment-related toxicities, addressing the challenges faced in current cancer therapies. The patent provides detailed methods and compounds for treating various types of solid tumors, emphasizing the importance of neutrophil suppression in improving the efficacy of oncolytic bacterial therapy. [Extracted from the article]

The article discusses a clinical trial, NCT06643585, comparing Trastuzumab-Deruxtecan to standard therapy in HER2-positive or HER2-low early breast cancer patients with molecular relapse. The trial aims to evaluate ctDNA clearance rate after 12 months between the two treatment arms. The study is interventional, phase III, and randomized, with recruitment not yet started and an enrollment target of 180 participants by December 1, 2031. The eligibility criteria include specific age ranges, breast cancer diagnosis, and compliance with study procedures, while exclusion criteria involve certain medical conditions and history of specific treatments. [Extracted from the article]

A clinical trial, NCT06643000, aims to evaluate the efficacy of high-dose furmonertinib combined with bevacizumab and pemetrexed in treating non-small cell lung cancer (NSCLC) with leptomeningeal metastasis and EGFR mutations. The study will assess overall survival, time to treatment failure, leptomeningeal objective response rate, and clinical response rate, as well as quality of life and safety. The trial targets 60 eligible NSCLC patients with EGFR mutations and leptomeningeal metastasis, using a combination of furmonertinib, bevacizumab, and pemetrexed administered every 3 weeks. [Extracted from the article]

A clinical trial, NCT06639958, aims to enhance adherence to 6-mercaptopurine (6MP) medication in children, adolescents, and young adults with acute lymphoblastic leukemia (ALL) during maintenance therapy at home. The trial involves using a special medication bottle fitted with a cap that electronically records when the bottle is opened to help patients remember to take their medication. The study will assess participation rates, refusal reasons, attrition rates, and completeness of the study, with a focus on improving 6MP adherence through different intervention packages. [Extracted from the article]